Verastem

Verastem Oncology is committed to advancing cancer treatment for patients with RAS/MAPK pathway mutations, a significant driver of tumor growth and resistance. Their innovative therapies, like the FDA-approved AVMAPKI FAKZYNJA CO-PACK, specifically target recurrent KRAS-mutated low-grade serous ovarian cancer, addressing a critical unmet need in oncology. With ongoing clinical trials and an expanding pipeline, Verastem is poised to make a substantial impact in the evolving landscape of cancer care.